Navigation Links
Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
Date:1/5/2009

Acquisition Adds Marketed Products and Specialty Sales Force in Urology and Endocrinology, Novel Drug-Delivery Technology

Combined Pipeline to Include Nine FDA-Approved Therapeutics

Conference Call Scheduled for Today at 5:30 pm EST

CHADDS FORD, Pa. and LEXINGTON, Mass., Jan. 5 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) and Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today that they have entered into a merger agreement under which Endo will commence a tender offer to acquire 100 percent of the outstanding shares of Indevus for approximately $370 million, or $4.50 per Indevus share, in cash, and up to an additional approximately $267 million, or $3.00 per Indevus share, in cash payable in the future upon achievement of certain regulatory and sales milestones. The transaction has been approved by the boards of directors of both companies.

David Holveck, president and chief executive officer of Endo, stated, "This merger reflects our desire to expand our business beyond pain management into complementary medical areas where we can be innovative and competitive. We believe this expansion of our product line has significant growth potential because of the therapeutic value of the Indevus product portfolio, the unique expertise of both companies, and the demographic, health care and reimbursement trends that favor the consideration of new products to address unmet needs in urology and endocrinology.

"These trends demand that pharmaceutical companies become better health care partners with physicians and managed care organizations by offering a range of new products and technologies in related medical specialties that achieve better outcomes for patients. Thi
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...wire/ -- Acuo Technologies, developers of high-per...igration tools and services, today announced a new...ge sharing across the networks of hospitals, clini...is based on the versatile Acuo Technologies DICOM ...ables secure access from various PACS to medical i...
(Date:11/29/2009)...A-Line Athletic Mat is great. It,s a very good de... physician best known for establishing and popular...ww.yogaforce.com and order the new Mat today for ... San Francisco, CA (PRWEB) November 2...Force newly patented, revolutionary A-Line Athleti...
(Date:11/28/2009)...change after 30-minute psychosocial intervention, ...ay News) -- A program that gets persistent drunk d...erous behavior may lead to significant and long-la...w study included 184 men and women with two or mor...domly assigned to one of two interventions. The fi...
(Date:11/27/2009)... Uploadable USB pedometers may be new, but they,re...ion of advanced accelerometer functionality and au...n over the accuracy of self-reported data. It,s no... participation in a fitness program. ,, CoreHea...liers to integrate this technology. "Our health ch...
(Date:11/27/2009)...re-USNewswire/ -- Preventing disease is the goal o... year, new vaccines are being added to assist in d...ity for the same period of time? And, if not, when...unity strong? ,, In this month,s issue of Ped...diatrics, Michael Pichichero MD, Director of the R...
Breaking Medicine News(10 mins):Health News:Acuo Technologies Announces a New Offering That Enables Sharing of Imaging Studies Securely and Affordably 2Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 2Health News:The YogaForce A-Line Mat Provides The Perfect Solution For Fitness Needs 3Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3
...carbohydrate diet changes hepatic energy metabolis...lies more on substances like lactate and amino aci...dings are in the November issue of Hepatology, a...nline at Wiley Interscience ( www.interscience.wil...
...rvice Members to Be Served Beginning in ...t. 20 United Concordia Companies,Inc. has been aw...DP),contract by the United States Department of De... approximately,$660 million, will begin August 1, ...
... economic,slowdown reinforces the need for employe...es -- through programs to promote prevention, well...e Continuum Alliance says., "Tough economic times...c condition management programs contribute to,that...
... chances of survival, study found , , MOND...for someone with non-Hodgkin lymphoma increases if...chemotherapy, a new study shows. , The report, pub...ath from the disease than whites. , Non-Hodgkin ly...
...Concentric Medical,Inc., the global leader in devi...today announced the launch of the Merci(R) Distal ...erventionalists easier distal,access and enhanced ...patients suffering an ischemic stroke., The Merci...
...lan incorporates new management and technology inf... Alpharetta, GA (Vocus) Octobe...his country is in crisis, that it is unaffordable ...tice rates. But according to Richard Jackson, Chai...
Other Medicine News:Health News:Low-carb diets alter glucose formation by the liver 2Health News:Low-carb diets alter glucose formation by the liver 3Health News:National Dental Insurer United Concordia to Receive $660 Million Contract From U.S. Department of Defense 2Health News:Employee Health Promotion More Important Than Ever in Economic Crunch 2Health News:CEO Proposes a Radical Plan to Revamp the Healthcare System 2Health News:CEO Proposes a Radical Plan to Revamp the Healthcare System 3
(Date:11/28/2009)..., , CHICAGO, Nov. 28 S...w generation of its Tim ® (Total imaging mat...mizing throughput) engine. Both technologies are i...sla (T) and the new MAGNETOM Skyra* 3T scanners at...f the Radiological Society of North America (RSNA)...
(Date:11/27/2009)..., , SALT LAKE CITY, Nov. 27 /PRNewswir... Medical Systems, Inc. (NYSE: VAR ), a premier s...e detectors, will exhibit its full range of detect...om November 29 - December 3, 2009. Varian will al...e modalities as well as specialized cancer treatme...
(Date:11/27/2009)..., , CHICAGO, Nov. 27 ...ica (RSNA) annual meeting starting Sunday, Royal P...te a new range of healthcare imaging and informati...rities of patients and care providers, by deliveri...esire for value, modular price points and easy upg...
Breaking Medicine Technology:Siemens Introduces Its New Power Couple at RSNA 2009 2Siemens Introduces Its New Power Couple at RSNA 2009 3Siemens Introduces Its New Power Couple at RSNA 2009 4Siemens Introduces Its New Power Couple at RSNA 2009 5Siemens Introduces Its New Power Couple at RSNA 2009 6Siemens Introduces Its New Power Couple at RSNA 2009 7Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4New book teaches core skills needed to create professional scientific communications 10155 1New book teaches core skills needed to create professional scientific communications 10155 2New book teaches core skills needed to create professional scientific communications 10155 3Telltale moss 10152 11918 Flu Closings May Provide Lessons for Today 58460 11918 Flu Closings May Provide Lessons for Today 58460 2
...any (NYSE: BMY ) today announced new data from th...f antiviral-naive adult chronic hepatitis B,patien...er long-term viral,load reduction than adefovir at...ts (primary endpoint). Suppression of viral load t...eatment response and is an important,goal of chron...
...: DCTH ) announced today that the Institutional R...dical Center (UMMC) has approved UMMC,s,participat...aneous Hepatic,Perfusion (PHP) System for the isol...melphalan to treat inoperable metastatic melanoma ...g led by the National Cancer,Institute (NCI), whic...
Other Medicine Technology:BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 2BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 3BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 4BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 5BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 6BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 7Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center 2Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center 3Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center 4
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
Medicine Products: